Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
ACS Applied Energy Materials
|
November 2, 2020
Different Photostability of BiVO<sub>4</sub> in Near-pH-Neutral Electrolytes
Siyuan Zhang, Ibbi Ahmet, Se-Ho Kim, et al.
The Oncologist
|
January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up
Richard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Journal of the National Cancer Institute
|
July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
Véronique Diéras, Hope S Rugo, Patrick Schnell, et al.
The Oncologist
|
May 6, 2021
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3
Hiroji Iwata, Yoshiko Umeyama, Yuan Liu, et al.
Cancer Medicine
|
March 11, 2015
Complex renal cysts associated with crizotinib treatment
Patrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2018
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Hope S Rugo, Nicholas C Turner, Richard S Finn, et al.
Breast Cancer Research : BCR
|
June 29, 2016
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
Richard S Finn, John P Crown, Johannes Ettl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Clinical Pharmacology and Therapeutics
|
October 20, 2021
Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men
Albert L Kraus, Michelle Yu-Kite, Jack Mardekian, et al.
Frontiers in Oncology
|
May 16, 2022
Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
Jharna Datta, Natalie Willingham, Jasmine M Manouchehri, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
ACS Applied Energy Materials
|
November 2, 2020
Different Photostability of BiVO<sub>4</sub> in Near-pH-Neutral Electrolytes
Siyuan Zhang, Ibbi Ahmet, Se-Ho Kim, et al.
The Oncologist
|
January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up
Richard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Journal of the National Cancer Institute
|
July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
Véronique Diéras, Hope S Rugo, Patrick Schnell, et al.
The Oncologist
|
May 6, 2021
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3
Hiroji Iwata, Yoshiko Umeyama, Yuan Liu, et al.
Cancer Medicine
|
March 11, 2015
Complex renal cysts associated with crizotinib treatment
Patrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2018
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Hope S Rugo, Nicholas C Turner, Richard S Finn, et al.
Breast Cancer Research : BCR
|
June 29, 2016
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
Richard S Finn, John P Crown, Johannes Ettl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Clinical Pharmacology and Therapeutics
|
October 20, 2021
Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men
Albert L Kraus, Michelle Yu-Kite, Jack Mardekian, et al.
Frontiers in Oncology
|
May 16, 2022
Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
Jharna Datta, Natalie Willingham, Jasmine M Manouchehri, et al.
Page
of 4